Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talquetamab + daratumumab + lenalidomide
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This is an investigational combination regimen comprised of **talquetamab**, **daratumumab**, and **lenalidomide**, being evaluated for the treatment of multiple myeloma. Talquetamab is a bispecific monoclonal antibody that engages T-cells to target GPRC5D-expressing plasma cells. Daratumumab is a monoclonal antibody targeting CD38 on myeloma cells, inducing cell death by direct cytotoxicity and immune modulation. Lenalidomide is an immunomodulatory small molecule enhancing immune cell activation and anti-tumor responses. The combination aims to simultaneously target distinct myeloma antigens and augment immune-mediated cytotoxicity for deeper and more durable responses in relapsed or refractory multiple myeloma[1][2][3][5][6].
- Other names
- Talquetamab plus Daratumumab plus LenalidomideTal-D-Len
02
Targets
CD38 (Cluster of Differentiation 38)CD3 (T-cell surface glycoprotein CD3)CRBN (Cereblon)GPRC5D
Beyond the preview
Go deeper on talquetamab + daratumumab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talquetamab + daratumumab + lenalidomide.